Drug intelligence / Profile preview

NORDBIOTIC Target-shield

Development stage: Preclinical
Lead developer: Nordic Biotic
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

NORDBIOTIC Target-shield is a probiotic dietary supplement developed by Nordic Biotic, specifically formulated for co-administration with antibiotic therapy. The product utilizes a combination of bacterial strains selected for their antibiotic compatibility, meaning they are designed to survive and remain functional in the gastrointestinal tract even when antibiotics are present. This formulation aims to mitigate the disruptive effects of antibiotics on the gut microbiome (dysbiosis) and support overall gastrointestinal health during treatment. Currently, the product is supported by in vitro studies demonstrating its resilience to various antimicrobial agents.

Brand names: NORDBIOTIC Target-shield
Other names: Nordic Biotic Target-shield

Beyond the preview

Go deeper on NORDBIOTIC Target-shield.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NORDBIOTIC Target-shield.

Explore the full profile